Skip to main content
Figure 1 | Journal for ImmunoTherapy of Cancer

Figure 1

From: Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma

Figure 1

Higher dose and longer duration of α-PD-L1 mAb treatment does not improve survival, suggesting resistance to α-PD-L1 mAb treatment. Mice were injected with K7M2 cells, and treated for either 15 days (n = 10) or 30 days (n = 10) with α-PD-L1 mAb. Survival was not significantly different between the 15 day and 30 day treatment, p = 0.2942, and all mice succumbed to disease (A). At time of necropsy, PD-L1, CD80, and CD86 expression was evaluated using Flow Jo. PD-L1 expression was significantly decreased in treated versus untreated mice, p = 0.0026. CD80 expression was significantly increased in treated versus untreated mice, p < 0.0001. CD86 expression was significantly increased in treated versus untreated mice, p < 0.0001 (B). At time of necropsy, PD-1+, CTLA-4+, and LAG3+ CD8+ expression was evaluated using Flow Jo. PD-1 + CD8+ expression was significantly different in treated versus untreated mice, p = 0.0005 (C). CTLA-4 + CD8+ expression was significantly different in treated versus untreated mice, p = 0.043 (D). LAG3 + CD8+ expression was not significantly different between treated and untreated mice (E).

Back to article page